

# Introduction to sequencing: Sequencing technology and preprocessing of sequencing data

Koen Van den Berge

Last compiled on 07 December, 2021

## Contents

<b>1</b>	<b>Sequencing technology</b>	<b>1</b>
1.1	The bulk RNA-seq workflow . . . . .	1
1.2	The sequencing output files . . . . .	2
<b>2</b>	<b>Preprocessing of raw sequencing data</b>	<b>4</b>
2.1	Quality control . . . . .	4
2.2	Mapping . . . . .	4
2.3	Abundance quantification . . . . .	9

## 1 Sequencing technology

- Measuring mRNA molecules typically happens through sequencing.
- The technology continues to evolve at an incredible speed. The data output of so-called ‘next generation’ sequencing machines has more than doubled each year! Simultaneously, the cost of sequencing (in terms of \$ per Gigabase) is dropping. Each year, we’re able to sequence more for less money, providing more information, as well as also computational and statistical challenges.
- This tremendous technological revolution has revolutionized biology, and genomic sequencing is now a core component of the modern-day biologist’s toolkit.
- The large majority of sequencing data is generated using sequencing-by-synthesis using machines produced by the company Illumina. While new players such as Pacific Biosciences and Oxford Nanopore have entered the scene, these are typically most useful for (but not limited to) DNA sequencing rather than gene expression studies, owing to their capability of sequencing long molecules.

### 1.1 The bulk RNA-seq workflow

Library preparation steps:

1. First, the biological **samples of interest are collected**. Owing to the maturity of different protocols for sequencing, several types of biological input samples are amenable to sequencing, such as frozen tissues or FFPE-preserved samples.



**Figure 2: Human Genome Sequencing Over the Decades**—The capacity to sequence all 3.2 billion bases of the human genome (at 30 $\times$  coverage) has increased exponentially since the 1990s. In 2005, with the introduction of the Illumina Genome Analyzer System, 1.3 human genomes could be sequenced annually. Nearly 10 years later, with the Illumina HiSeq X Ten fleet of sequencing systems, the number has climbed to 18,000 human genomes a year.

Figure 1: Figure: The data output revolution of sequencing machines. Image from Illumina documentation.

2. The **(m)RNA molecules from our sample are captured**. This typically involves cell lysis in order to release the (m)RNA molecules from within the cells. The mRNA molecules are most often captured using (i) polyA-capture to select for polyadenylated RNA, or (ii) ribosomal depletion, where ribosomal and transfer RNAs are depleted, and so also non-polyA-mRNA molecules may be captured, such as micro RNAs. In the case of ‘targeted sequencing’, where relevant molecules are of main interest (e.g., a gene panel), these targets can be specifically targeted in this step.
3. **Fragmentation** of captured molecules. The captured molecules are fragmented, either chemically or mechanically. The appropriate size of fragments depends on the sequencing machines, but is often in the range of 300 - 500bp.
4. **Reverse transcription**. Current dominant sequencing machines only sequence double-stranded DNA molecules. Therefore, in order to measure single-stranded mRNA, we must first reverse transcribe these molecules to a double-stranded complementary (cDNA) molecule.
5. **Adapter ligation**. Adapters are oligonucleotides (short sequences of nucleotides) that are platform-specific sequences for fragment recognition by the sequencing machines. These are added either to the 3' or 5' end of the cDNA molecules or used as primers in the reverse transcription reaction. The final cDNA library consists of cDNA inserts flanked by an adapter sequence on each end.
6. **PCR amplification**. To increase concentration, several PCR reaction cycles are performed.
7. Loading the amplified cDNA library on the **sequencing** machine. Find out how sequencing-by-synthesis works through this video. Note that the video shows paired-end sequencing, where a number of basepairs are sequenced at each end of the fragment. All previous steps together are described as ‘sample prep’ in that video.

## 1.2 The sequencing output files

- The typical output of a sequencing machine we will be working with are FASTA or FASTQ files for each sample. Each of these files are several gigabases large and contain millions of sequences, which we will call **reads**. For paired-end sequencing, there are two files for each sample, one for each end of the sequenced fragments.
- The difference between a FASTA file and a FASTQ file, is that while FASTA files only store the results of base calls (sequences), FASTQ files also store the quality score of each base call (i.e., each called nucleotide), which can be useful in downstream analyses such as mapping or variant calling.



Figure 2: Figure: The sequencing workflow. Image adapted from Van den Berge et al. (2019).

- A FASTQ file contains four lines for each sequenced read:
  1. Sequence identifier line, starting with @.
  2. The sequence.
  3. Another sequence identifier line, now starting with +.
  4. Quality scores.

### FASTQ format - sequence ID line

---

```
@D7MHBFN1:202:D1BUDACXX:4:1101:1340:1967 1:N:0:CATGCA
NATCTCGGATCACTTGGTCAAATTGAAACGATACTAGAGATTGTAAGTAACAATATTACCAAGGTTGAGTCATACTA
ACTCGTTGTCCCTAGT
+
#1=DDFFFHHHHHJJJJJJJJHIIJIIJJIIJGIIIIJJJJIIJIIJJHIIFGIIIIJJJJIIIEHJIIHHGFFF@?ADFEDDED
CDBBDBDCDDDEC
```

---

- D7MHBFN1 - unique instrument name
- 202 - run ID
- D1BUDACXX - flowcell ID
- 4 - flowcell lane
- 1101 - tile number within lane
- 1340 - x-coordinate of cluster within tile
- 1967 - y-coordinate of cluster within tile
- 1 - member of pair (1 or 2). Older versions: /1 and /2
- Y/N - whether the read failed quality control (Y = bad)
- 0 - none of the control bits are on
- CATGCA - index sequence (barcode)

Figure 3: Figure: One read in a FASTQ file. Slide courtesy by Charlotte Soneson.

As you'll have noticed, the base call quality scores are encoded as ASCII characters for efficient storage. These ASCII characters can be converted into integers called Phred scores, which are logarithmically related to the probability of an erroneous base call.

## 2 Preprocessing of raw sequencing data

After sequencing, we typically do a quality control (QC) check to verify the quality of the samples. During QC check, aberrant samples due to e.g. degraded mRNA can be detected.

The sequencing reads on their own contain a lot of information, but are most useful if we would be able to assign sequencing reads to genomic features (genes, exons, transcripts, etc.), i.e., for each sequencing read we will try to derive the (set of) feature(s) that could have plausibly produced the fragment through the process of gene expression. This process is called **mapping**. Most often we map reads to genes.



Figure 4: Figure: An updated sequencing workflow, including sequencing and mapping. Image adapted from Van den Berge et al. (2019).

### 2.1 Quality control

During quality control, diagnostic plots are created for each sample in order to determine its quality. The most popular QC tool for bulk RNA-seq data is FastQC. If many samples are sequenced, then MultiQC can be used to aggregate the QC checks across samples in a conveniently organized overview.

The FastQC website provides interesting example reports for us to look at and compare against. Here are example reports of high-quality Illumina data and low-quality Illumina data.

### 2.2 Mapping

- Mapping is a critical step in the interpretation of RNA-seq data, where we are attributing reads to genomic features.
- Allows us to measure how strong a feature such as a gene is expressed: the number of reads mapping to a gene serve as a proxy for how high that gene has been expressed in the sample.
- While this opens the door to many opportunities, mapping is hard.
- We are **typically unable to assign each individual read uniquely** to one specific gene; some reads cannot be unambiguously mapped and are compatible with multiple genes. These reads are said to be ‘multi-mapping’.

Finally, a note on terminology. In this text we will use the words ‘read’ or ‘fragment’ (referring to the fragmented mRNA molecule being sequenced) to designate a datum, note that this could be either a single read (in single-end sequencing) or a read pair (in paired-end sequencing). The literature may also use these words interchangeably, although ‘fragment’ seems better at avoiding ambiguity between single-end reads and paired-end read pairs.

### 2.2.1 Reference files

- The alignment most often relies on a **reference genome** of the species, which can be considered a ‘representative example’ of the genome sequence of that species. Reference genomes are continuously updated and released periodically.
- Reference genomes can be freely downloaded from several providers, for example Ensembl or Gencode.
- Along with a reference genome, an annotation GFF or GTF file defines the coordinates of specific genomic features.
- While here we will focus on reference-based alignment, i.e., alignment where a reference genome or transcriptome is available, note that a *de novo* construction of a reference transcriptome is also possible, where the reference may be constructed from the observed sequencing reads.



```
human — more - sh - /usr/bin/zmore Homo_sapiens.GRCh37.67.dna.toplevel.fa.gz — 111x34
:ACCTAACCTAACCTAACCTAACCCAACCTAACCTAACCTAACCTAACCTAACCTAACCTAA
CCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAA
CCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAAC
TAACCTAACCTAACCTAACCTAACCCAACCTAACCCAACCTAACCCAACCTAACCTAAC
CAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAAC
TAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAACCTAAC
CCCTAACCTAACCTAACCTAACCTCGGGTACCTCAGCCGCCGCCGCCGCCGCCGCCGCC
TCTGACCTAGGAGAACTGTCTCCGCCTCAAGAGTACCCAGGAATCTGTGAGAGGAC
AACGAGCTCCGGCCCGCGCCGGCGAGCGCAAGAGAGCGCCGCCGCCGCCAGGGCG
GTTCGAAAGCCGCCCGCGCCGGCGAGCGCAAGAGAGCGCCGCCGCCGCCAGGGCG
CAGAGAGGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCAGGGCG
GAGAGGCCGCCGCCGCCGCCGCCAGGGCGAGAGAGGCCGCCGCCGCCGCCAGGGCG
CACATGCTAGCGCGTGGGGTGAGGCCTGGCCAGGGCGAGAGAGGCCGCCGCCGCC
CGCAGGGCAGAGACACATGCTACCGCGTCCAGGGGTGGAGGGCTGGCGCAGGGCG
AGGGCGCACCGCGCCGGCGCAGGGCGAGAGACACATGCTAGCGCGTCCAGGGGTGGAGGG
TGGCGCAGGGCGAGAGACCGCAAGCCTACGGGCGGGGGTTGGGGGGCGTGTGAGGA
GCAAAGTCCACGCCGCCGGCTGGGCAGGGGAGGGTGGCCCGTGCACCGGGAGAAA
CTCACGTCACGGTGGCGCGCAGAGACGGGTAGAACCTCAAGTAATCGAAAAGGCCGG
ATCGACCGCCCCCTGCTTGCAGGGGACTACAGGACCCGCTTGCTCACGGTGCTGTC
CAGGGCGCCCCCTGCTGGCGACTAGGGCAACTCAGGGCTCTTGCTTAGAGTGGTGG
CAGGCCCGCCCTGCTGGCGCAGCTAGGGACATTGCAAGGGTCTCTCTCAAGGTGTAGTGGCA
CACGCCCGCCCTGCTGGCGCAGCTAGGGACATTGCAAGGGTCTCTCTCAAGGTGTAGTGGCA
GCACGCCCGCCCTGCTGGCGCAGCTGGGAGCATATGCTTTGGTCTCAAGTACTCTAAATATG
GGATTCTGGTTAAAAGTAAAAAATAATATGTTAATTGTAAGTGTGATTACCATCA
GAATTGTAATGTTCTGTAATCCCACCAAGCAATGTCAGGAATGCCGTGTTCTCCACAAAGT
GTTTACTTTGGATTGGTCAACAGGTGAAGGCCCTGGAGATTCTTATTAGTGAT
TTGGCTGGGCCCTGGCCATGTTATTTTAAATTTCAGTGATGATTGCTGGCATG
GCCGGTGTGGAGAAATGACTGCCGAATTGGCGGATTTCCTTGCTGTTCTGCATGTAG
TTAAACGAGATGCCAGCACGGGTATCCTACCAATTTCCTTCTGTTAACTTGGCG
TCAGCTTCTTCTTCACTCTTCTGTTCACTGTTGATTGCTGCTCTTAAGCCAGA
CTTCCCGTGTGCTTCACTGCCACGGGCTTGGAGAGGTACAGGGCTTGATGCTGTT
CATCTGCAGGTGTGACTTCCACCAACTGCTGGCCCTGTGCCAGGGTCAAGCTGAGCAC
:|
```

Figure 5: Figure: A reference sequence of human chr1.

- More recently, mapping of RNA-seq data occurs more often against a **reference transcriptome**, which is a reference file containing the sequences all known isoforms of a particular species, e.g., using kallisto or Salmon.
- The set of spliced transcripts is much smaller than the entire genome, and therefore mapping against a reference transcriptome is typically **fast and memory efficient**.

```

gtf --bash -- 154x42
(base) Koens-MacBook-Pro:gtf koenvandenberghe$ cat test_ensemble_chr22.gtf
22 protein_coding UTR 12791 14009 . + . ccds_id "CCDS14010"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding exon 12791 14103 . + . ccds_id "CCDS14010"; exon_id "ENSE00001343011"; exon_number "1"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding transcriptpt 12791 101082 . + . ccds_id "CCDS14010"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 miRNA exon 13518 13571 . + . exon_id "ENSE00001564868"; exon_number "1"; gene_biotype "miRNA"; gene_id "ENSG00000221160"; gene_name "MIR1281"; gene_source "ensembl"; transcript_id "ENST00000408233"; transcript_name "MIR1281-201"; transcript_source "ensembl"; tss_id "TSS185001";
22 miRNA transcript 13518 13571 . + . gene_biotype "miRNA"; gene_id "ENSG00000221160"; gene_name "MIR1281"; gene_source "ensembl"; transcript_id "ENST00000408233"; transcript_name "MIR1281-201"; transcript_source "ensembl"; tss_id "TSS185001";
22 protein_coding CDS 14010 14103 . + 0 ccds_id "CCDS14010"; exon_number "1"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; protein_id "ENSP00000263253"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding start_codon 14010 14012 . + 0 ccds_id "CCDS14010"; exon_number "1"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding CDS 38192 38826 . + 2 ccds_id "CCDS14010"; exon_number "2"; gene_biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; protein_id "ENSP00000263253"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding exon 38192 38826 . + . ccds_id "CCDS14010"; exon_id "ENSE00000654991"; exon_number "2"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding CDS 46869 47045 . + 0 ccds_id "CCDS14010"; exon_number "3"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; protein_id "ENSP00000263253"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding exon 46869 47045 . + . ccds_id "CCDS14010"; exon_id "ENSE00000655017"; exon_number "3"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding CDS 48492 48753 . + 0 ccds_id "CCDS14010"; exon_number "4"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; protein_id "ENSP00000263253"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding exon 48492 48753 . + . ccds_id "CCDS14010"; exon_id "ENSE00000655023"; exon_number "4"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";
22 protein_coding CDS 50895 51008 . + 2 ccds_id "CCDS14010"; exon_number "5"; gene.biotype "protein_coding"; gene_id "ENSG00000100393"; gene_name "EP300"; gene_source "ensembl_havana"; p_id "P5137"; protein_id "ENSP00000263253"; tag "CCDS"; transcript_id "ENST00000263253"; transcript_name "EP300-001"; transcript_source "ensembl_havana"; tss_id "TSS138009";

```

Figure 6: Figure: An example GTF file.

- However, it has been noted that mapping against a reference transcriptome may also introduce spurious expression for genes that are not expressed. These observations can be explained by **intronic reads** that share some sequence similarity with transcripts, and could map to spliced transcript sequences. Recent methods, such as alevin-fry, avoid this by expanding the reference transcriptome to also include intronic sequences.

### 2.2.2 Alignment-based workflows

- Traditionally, alignment-based workflows have been used to map reads, where one tries to **find the exact coordinates a read maps to** on the reference genome or the reference transcriptome.
- Note that due to alternative splicing, reads do not necessarily map contiguously on a reference genome, as a read can overlap with a splicing junction, where an intron has been excised. When mapping against a transcriptome, however, reads should be mapping contiguously.
- A main challenge in spliced alignment against a reference genome is the proper alignment of reads that span a splice junction, especially when these junctions are not annotated a priori. Indeed, in spliced alignment reads can be split at any nucleotide, and the corresponding subsequences can map several thousands of basepairs apart. Meanwhile, the main challenge in unspliced alignment to a transcriptome is the redundant sequence among related transcripts in the transcriptome, which often leads to a high multi-mapping rate (i.e., reads that cannot be unambiguously assigned to a single transcript).
- Spliced alignment against a genome is therefore computationally a much harder task. Since the transcript sequences are already spliced when aligning to a reference transcriptome, reads should align contiguously, and many of the computationally expensive steps and heuristics can be avoided, there.

### 2.2.3 Alignment-free workflows

- Modern approaches **avoid mapping each fragment individually** (i.e., do not attempt to find the exact coordinates of a read's origin), and instead posit a probabilistic model where **transcript**



**Figure 4**

An illustration of spliced alignment of RNA sequencing (RNA-seq) fragments to a genome (*a*) and direct alignment to a transcriptome (*b*). Reads are designated by thick solid lines, while dashed arcs represent the pairing relationship between paired-end reads. This illustration depicts alignment to a single four-exon gene consisting of three distinct transcripts. In the spliced alignment (*a*), the left read of the rightmost pair is a junction-spanning alignment to the red-green exon boundary. In the direct alignment to the transcriptome (*b*), one observes how the same alignment (e.g., the alignment to the blue exon) is repeated for each transcript.

Figure 7: Figure: Unspliced and spliced alignment. Figure from Van den Berge et al. (2019).

abundances are typically defined using its constituent  $k$ -mers. These methods are sometimes referred to as *lightweight*.

- A  $k$ -mer is a short sequence of nucleotides of length  $k$ . The space of possible  $k$ -mers and the corresponding transcripts can be precomputed in advance using the reference transcriptome, providing a computational advantage as it only needs to be computed once.
- For each fragment, the transcripts its  $k$ -mers are compatible with is searched for using an indexed (efficiently searchable) transcriptome. The set of compatible transcripts is called the ‘ $k$ -compatibility class’, ‘equivalence class’ or ‘transcript compatibility class’ of the fragment.



**Figure 1** Overview of kallisto. The input consists of a reference transcriptome and reads from an RNA-seq experiment. (a) An example of a read (in black) and three overlapping transcripts with exonic regions as shown. (b) An index is constructed by creating the transcriptome de Bruijn Graph (T-DBG) where nodes ( $v_1, v_2, v_3, \dots$ ) are  $k$ -mers, each transcript corresponds to a colored path as shown and the path cover of the transcriptome induces a  $k$ -compatibility class for each  $k$ -mer. (c) Conceptually, the  $k$ -mers of a read are hashed (black nodes) to find the  $k$ -compatibility class of a read. (d) Skipping (black dashed lines) uses the information stored in the T-DBG to skip  $k$ -mers that are redundant because they have the same  $k$ -compatibility class. (e) The  $k$ -compatibility class of the read is determined by taking the intersection of the  $k$ -compatibility classes of its constituent  $k$ -mers.

---

## 2.3 Abundance quantification

Given a set of mappings, using either alignment-based or alignment-free workflows, the estimation of expression of a gene/transcript/exon may occur in several ways.

### Counting:

- In alignment-based workflows, one could do a direct counting of fragments at, for instance, the gene level, counting the number fragments mapping to each gene. This has been the dominant approach for the first decade of RNA-seq data, often obtained using reference genome alignments.
- Many heuristic choices need to be made: Do we count a fragment as soon as it intersects with the gene's coordinates, or do we require the full fragment to map to the gene? Do we count intronic reads? Do we count multi-mapping reads?

### Estimation:

- Abundance quantification is more recently starting to shift from counting towards using statistical models to estimate the expression counts for a feature, which in this case is typically a transcript.
- This approach is amenable to alignment-free workflows, since the number of fragments in each equivalence class are sufficient statistics for the abundance quantification, meaning that they contain all information needed to estimate the parameters of the statistical model, and hence the feature-level abundances. Since the expression counts in this case are estimated, they are not necessarily integer counts, and will be referred to as 'estimated counts'.
- In order to derive these, the EM-algorithm (Dempster *et al.* (1977)) is often used, although other approaches have been used by tools like Salmon. A big advantage of the estimation approach is that it **probabilistically assigns fragments to transcripts, thereby automatically dealing with multi-mapping reads**. The total number of fragments mapping to each transcript is then the sum of all fragment-level probabilities to be assigned to that respective transcript.

### 2.3.1 The final countdown

Once abundances have been quantified, the (estimated) counts are typically stored in a count matrix, with genes spanning the rows and samples spanning the columns. This count matrix forms the basis of most downstream analyses to interpret RNA-seq data, and it will be the main object we will be working with in the following lectures.



Figure 8: Figure: Gene- and exon-level read counting. Image adapted from Charlotte Soneson.



**Figure 5**

An illustration of the alignment of various reads to a gene with three isoforms: blue (B), green (G), and red (R). In this example, we wish to estimate the abundances of these isoforms, but most reads have ambiguous origins and need to be probabilistically assigned to the transcripts (relative probabilities for each read are shown by the magnitudes of the three colors). Some reads are consistent only with the B and G transcripts, and a few reads uniquely align to a single transcript (single color). In the expectation-maximization (or related) algorithm, given the current abundance estimates, fragments are probabilistically assigned to transcripts, and then estimated abundances are updated by summarizing the (proportional) allocations over all fragments; transcript abundance estimates are determined by iterating the procedure until convergence.

Figure 9: Figure: Abundance quantification using the EM algorithm. Figure from Van den Berge et al. (2019).



Figure 10: Figure: An updated sequencing workflow. Image adapted from Van den Berge et al. (2019).